Shares in Heron Therapeutics (NSDQ:HRTX) rose today after the biotech reported that the FDA gave priority review status to its investigational postoperative pain drug. The company’s HTX-011 product is a long-acting formulation of bupivacaine in combination with the anti-inflammatory meloxicam. Heron touts the product as the first dual-action, fixed-combination drug designed to address postoperative pain […]
